Can tiny bubbles make heart scans crystal clear?

NCT ID NCT07740421

Not yet recruiting Diagnosis Sponsor: Trust Bio-sonics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether an experimental contrast agent called NH002 can improve the quality of heart ultrasound images in adults with suspected or known heart disease. The agent is given as an injection or infusion and contains tiny microbubbles that help outline the heart's inner chambers. Researchers will compare images taken with and without the contrast to see if it makes the heart's borders easier to see, which could help doctors diagnose heart conditions more accurately.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NH002 (perflutren lipid microspheres), an injectable microbubble contrast agent
What this could lead to: If successful, NH002 could become a standard contrast agent to improve heart ultrasound clarity, helping doctors see heart chambers better without more invasive tests.
What could go wrong: This is a phase III trial, but results may not confirm benefit or safety in all patients. Contrast agents carry risks like allergic reactions or rare serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DISEASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.